▶주메뉴 바로가기
▶본문 바로가기
[ THE INVESTOR ] Shares of Samsung BioLogics rose 21.85 percent this year, becoming the biggest gainer among the large cap stocks on Korea’s main bourse KOSPI, according to Korea Exchange on May...
[ THE INVESTOR ] Korean botulinum toxin maker Hugel , which will be acquired by Bain Capital, has posted its highest operating profit on record in the first quarter, driven by strong exports of ...
[ THE INVESTOR ] The Korean unit of Swiss drug giant Novartis was slapped with a 55.1 billion won (US$48.80 million) fine and insurance coverage suspensions for giving illegal kickbacks to doctors ...
[ THE INVESTOR ] Celltrion Healthcare, the sales and marketing unit of Korean drug maker Celltrion , said on April 27 it has named Nippon Kayaku as its Japanese retail partner for Truxima. The J...
[ THE INVESTOR ] Korea’s Celltrion said April 26 that it has won all of its patent infringement suits involving Roche’s blockbuster breast cancer drug Herceptin in Korea, paving the way for the l...
[ THE INVESTOR ] Korean biotech firm Alteogen said April 26 has signed a letter of intent to license its long-acting drug for growth hormone deficiency with Brazil’s Cristalia for its developmen...
[ THE INVESTOR ] US pharmaceutical giant Pfizer said on April 26 it has promoted five executives at the Korean unit to manage positions in the Asia-Pacific region. Pfizer Korea Vice President Kim ...
[ THE INVESTOR ] Celltrion and its retail partner Pfizer plan to complete switching studies of the Korean drug maker’s biosimilar Inflectra, known as Remsima in Europe, to demonstrate its interch...
[ THE INVESTOR ] Korean biotech company Panagene plans to apply for regulatory approval of its own liquid biopsy testing in the US this year with aims to compete head-on with its bigger rival Roc...
[ THE INVESTOR ] South Korea’s Samsung Bioepis won the US Food and Drug Administration’s approval for its biosimilar copy of Johnson & Johnson’s Remicade on April 22, becoming a new challenger to ...
[ THE INVESTOR ] Alteogen is accelerating the development of a biosimilar version of the world’s top breast cancer drug Herceptin to join two other Korean firms in challenging big pharma Roche. ...
[ THE INVESTOR ] Daewoong Pharmaceutical said on April 19 that its generic antibiotic Meropenem has hit shelves in the US. Meropenem, which is used in treatment for a wide range of diseases rang...
[ THE INVESTOR ] SONGDO, Incheon -- Korea’s Celltrion will take away half of Johnson & Johnson’s Remicade market in the US with its biosimilar drug that hit the country last year, the company’s ...
[ THE INVESTOR ] Inside the plants of Celltrion at Songdo, Incheon, on a recent visit, there was a constant buzz as machines ran on full capacity to churn out 1.4 million biosimilar injection uni...
[ THE INVESTOR ] US private equity firm Bain Capital’s plans to acquire botulinum toxin maker Hugel has rattled its Korean rivals who are seeking to get a foothold in the US market. Besides Hug...
iPhone 8 unlikely to have curved edge display: source
Egg scare eases off in stock markets
Korean mobile carriers consider legal action against cost-cutting measures
Supply bottleneck to drag on for flexible OLED panels
Peter Thiel-backed Crescendo invests W60b in Hancom
Samsung Bioepis likely to launch first Herceptin biosimilar in EU
Demand for ultra-compact EVs rises in Korea
[DECODED X] Knock, knock, knocking on Samsung's door...
April 25, 2017
April 19, 2017
![[DECODED X] Knock, knock, knocking on Samsung's door...](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=152&simg=/content/image/2017/08/16/20170816001036_0.jpg&md=20170817115735)
